InvestorsHub on MSN
Record revenue growth and higher test pricing keep Exagen (XGN) in focus despite ongoing losses
Exagen delivered record first-quarter revenue and improved adjusted EBITDA metrics as the autoimmune diagnostics company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results